Why OKYO Pharma Limited’s (OKYO) Stock Is Down 6.85%
As of Wednesday, October 07, OKYO Pharma Limited’s OKYO share price has dipped by 6.85%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Commentary & Analysis
Why OKYO Pharma Limited’s (OKYO) Stock Is Up 5.22%
As of Friday, October 02, OKYO Pharma Limited’s OKYO share price has surged by 5.22%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why OKYO Pharma Limited’s (OKYO) Stock Is Up 5.30%
As of Friday, September 18, OKYO Pharma Limited’s OKYO share price has surged by 5.30%, which has investors questioning if this is right time to sell.Michael Rose
Why OKYO Pharma Limited’s (OKYO) Stock Is Up 5.97%
As of Wednesday, September 16, OKYO Pharma Limited’s OKYO share price has surged by 5.97%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why OKYO Pharma Limited’s (OKYO) Stock Is Down 5.04%
As of Wednesday, September 09, OKYO Pharma Limited’s OKYO share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | OKYO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $75.6 | $222.9 | 20% |
|
| Shares Out (Mil) | 37.3 | 53.4 | 41% |
|
| Institutional Ownership | 29.1% | 92.9% | 12% |
|
| Float (Mil) | 27.9 | 40.9 | 35% |
|
| Beta | 0.00 | 0.95 | 6% |
|
| Avg Daily Volume (000s) | 53 | 513 | 30% |
|
| Price Change (52-week) |
(35.7%) | 46.3% | 27% |
|
| Growth | OKYO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (21.2%) | (10.1%) | 19% |
|
| EPS (5yr) | 5.8% | 15.8% | 40 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (11.4%) | (15.7%) | 57% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | OKYO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($9) | ($44) | 30% |
|
| EPS (TTM) | ($0.240) | ($1.600) | 32% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($33) | 24% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $50 | $175 | 16% |
|
| Valuation | OKYO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.00 | 2.14 | 83% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | OKYO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.5% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (72.6%) | (47.2%) | 8% |
|
| ROE | (263.8%) | (53.5%) | 3% |
|
| Liabilities to Assets | 41.2% | 29.4% | 32% |
|
| F-Score | 4 | 2 | 34% |
|
OKYO Pharma Limited did not pass any screens on 10/26/2026.
